Pharsight and iBiomatics announce collaboration
The two companies predict the alliance will enable pharmaceutical researchers to design better clinical trials and make faster, more informed decisions during drug development.
By on Mar 12, 2001The two companies predict the alliance will enable pharmaceutical researchers to design better clinical trials and make faster, more informed decisions during drug development.
In the early stages of the collaboration, Pharsight and iBiomatics will market a solution designed to integrate Pharsight's Computer-Assisted Trial Design (CATD) methodology and the Pharsight Trial Simulator, with iBiomatics Web-based platform for biomedical informatics. The partnering companies predict that by allowing clinical trial planners to more easily share expertise and simulate possible outcomes, this solution will result in better, faster and more cost-effective clinical development programs.
"Pharsight and iBiomatics share a common goal of improving the efficiency of the R&D process," said Scott Neuville, CEO of iBiomatics. "In our collaboration with Pharsight, we seek to integrate the tools researchers use on a daily basis to develop and test clinical trial designs with a secure, Internet-based platform for biomedical informatics, providing a central source of knowledge for improving productivity in drug development planning."
There are additional plans for the two companies to collaborate on future projects to aid pharmaceutical research through the integration of their solutions. These plans are yet to be finalized.
"iBiomatics' platform for biomedical informatics provides an excellent framework for drug development organizations to capture and leverage internal expertise and best practices in clinical trial simulation," said Art Reidel, Pharsight President and CEO. "Working with iBiomatics should accelerate the transfer of Pharsight's advanced trial simulation technology and our scientific expertise to our customers by supporting knowledge sharing, mentoring, and collaboration."